Healthy Volunteers Clinical Trial
Official title:
Effect of Phototherapy Applied During Combined Training on Performance and Post-exercise Recovery: Study Protocol of a Randomized Controlled Trial by Stratified Sample, Double-blind, Placebo-controlled
Introduction: Recent studies have shown positive results from the application of
phototherapy for the improvement of performance and acceleration of the recovery process
both in the application before and after exercise. However, the effects of phototherapy
during combined training and after a primary adaptation process remain unclear.
Research objectives: The primary objective of the study is to analyze and compare the
effects of phototherapy using different light sources (laser and light emmiting diode - LED)
interacting with combined training on clinical, functional, and psychological outcomes and
vascular endothelial growth factor. The secondary objective is to compare the benefits
provided by phototherapy in participants with different levels of training adaptation.
Design: A controlled trial, double-blind, placebo-controlled will be conducted with
stratified randomization and concealed allocation.
Participants and Setting: After fulfilling the eligibility criteria, forty-five male
participants will participate in the study.
Procedure: In phase 1, the participants will perform six-weeks of combined training (sprints
and squats). In phase 2, participants will be allocated, through stratified randomization
(based on adaptation capacity to training), into three groups: active phototherapy group
(AG), placebo phototherapy group (PG), and control group (CG). A new six-week training
period will then start. In this phase the participants will carry out training normally with
the adjusted loads and between sprints and squats will receive the recovery strategy related
to the group to which they belong.
Intervention: Active and placebo phototherapy will be applied by a trained therapist,
between sprints and squats. During the period of recovery strategies for the AG and PG, the
CG participants will remain seated for passive recovery, supervised by an independent
therapist.
Measurements: The measurements include clinical, functional, and psychological outcomes and
vascular endothelial growth factor.
Introduction: Recent studies have shown positive results from the application of
phototherapy for the improvement of performance and acceleration of the recovery process
both in the application before and after exercise. However, the effects of phototherapy
during combined training and after a primary adaptation process remain unclear.
Research objectives: The primary objective of the study is to analyze and compare the
effects of phototherapy using different light sources (laser and LEDs) interacting with
combined training on clinical, functional, and psychological outcomes and vascular
endothelial growth factor. The secondary objective is to compare the benefits provided by
phototherapy in participants with different levels of training adaptation.
Design: A controlled trial, double-blind, placebo-controlled will be conducted with
stratified randomization and concealed allocation.
Participants and Setting: After fulfilling the eligibility criteria, forty-five male
participants will participate in the study. The inclusion criteria include: healthy male,
aged between 18-30 years who agree to participate in the study. Participants with the
following will be excluded from the study: presence of anemia, inflammation, diabetes,
history of metastasis or muscle injury in the lower limbs or spine in the previous six
months, and occurrence of musculoskeletal injury during the study.
Procedure: In phase 1, the participants will perform six-weeks of combined training (sprints
and squats). In phase 2, participants will be allocated, through stratified randomization
(based on adaptation capacity to training), into three groups: active phototherapy group
(AG), placebo phototherapy group (PG), and control group (CG). A new six-week training
period will then start. In this phase the participants will carry out training normally with
the adjusted loads and between sprints and squats will receive the recovery strategy related
to the group to which they belong.
Intervention: Active and placebo phototherapy will be applied by a trained therapist,
between sprints and squats, bilaterally to six sites of the quadriceps in direct contact
with the skin. The dosage applied will be 30J per site. The same procedures as the AG will
be applied to the PG, however the emitter will be disabled. During the period of recovery
strategies for the AG and PG, the CG participants will remain seated for passive recovery,
supervised by an independent therapist.
Measurements: The measurements include clinical (muscle soreness, pain threshold, perception
of exertion, and perception of recovery), functional (squat strength and power, maximal
voluntary isometric contraction, maximal incremental test, squat jump, and sprint test), and
psychological (self-assessments of readiness for exercise, fatigue, vigor, pain, and belief
of intervention effectiveness) outcomes and vascular endothelial growth factor.
Analysis: For analysis of functional outcomes, data normality will be checked by the
Kolmogorov-Smirnov test with changes from baseline followed by the Student T test for
comparisons. For other outcomes, sphericity of the data will be tested by the Mauchly's
test. In case of violation of the sphericity assumption, Greenhouse-Geisser corrections will
be used. Data will be analyzed using repeated-measures analysis of variance (Bonferroni's
test will be performed when required), which provide information on time, group, and
interaction effects. A significance level of 5% will be assumed for all statistical
analysis.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |